Biosensics

Focus: Biosensics is a biotech company specializing in wearable sensors and digital health technologies for neurological and neurodegenerative diseases. Founded in 2007 and headquartered in Newton, MA, the company focuses on remote monitoring and digital biomarkers across multiple rare and common neurological indications.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Biosensics

AI assessmentNot Hiring

No open roles listed right now. Follow Biosensics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

23 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Physical Activity Monitoring in Frailty and Falling

Fraility

N/A

Clinical Trials (1)

NCT01880229Physical Activity Monitoring in Frailty and Falling

N/A

Help build intelligence for Biosensics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer in digital health and wearable biomarkers for neurology—a growing market with significant unmet clinical needs across multiple indications
Diverse pipeline of 23 programs spanning Alzheimer's, Huntington's, ALS, stroke, and rare neuromuscular diseases, providing exposure to multiple therapeutic areas
Early-stage clinical activity (1 Phase 2 program in stroke) positioning the company for potential clinical and regulatory catalysts

Watch Out For

No active job openings reported and limited transparency on employee count, funding status, or financial performance suggest potential stagnation or operational challenges
Entirely pre-commercial pipeline with no marketed products or revenue streams; career stability depends entirely on securing financing and advancing programs
Lack of published research output (0 publications tracked) and absence of clear development phase assignments for most programs raise questions about scientific rigor and R&D velocity

Generated by Claude from Biosensics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Digital Speech and Handwriting Assessment

Amyotrophic Lateral Sclerosis

N/A

Clinical Trials (1)

NCT06315673Digital Assessment of Speech and Fine Motor Control in ALS

N/A

Wearable sensors and biofeedback

Stroke

N/A

Clinical Trials (1)

NCT03431025Wrist-worn Sensors for Tele-Rehabilitation of the Hemiparetic Upper Extremity

N/A

Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease

Huntington Disease

N/A

Clinical Trials (1)

NCT07315984Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease

N/A

Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (g

Myasthenia Gravis Generalized

N/A

Clinical Trials (1)

NCT07226830Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG

N/A

Wearable sensor

Myasthenia Gravis

N/A

Clinical Trials (1)

NCT06277830Physical Activity Monitoring in Myasthenia Gravis

N/A

Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis

Myasthenia Gravis

N/A

Clinical Trials (1)

NCT07224386Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis